Observation on the effect of intravenous thrombolysis with Recombinant Human Prourokinase in the treatment of acute ST-segment elevation myocardial infarction
XUE Hou-jun HE Ting
Department of Internal Medicine-Cardiology, the Second People′s Hospital of Honghu City in Hubei Province, Honghu 433200, China
Abstract:Objective To investigate the effect of intravenous thrombolysis with Recombinant Human Prourokinase in the treatment of acute ST-segment elevation myocardial infarction. Methods A total of 94 patients with acute ST-segment elevation myocardial infarction admitted to the Second People′s Hospital of Honghu City in Hubei Province from October 2018 to June 2020 were selected as the research objects, and they were divided into the control group (47 cases) and the observation group (47 cases) according to the odd-even method. The control group was treated with Urokinase thrombolytic therapy, and the observation group was treated with Recombinant Human Prourokinase therapy. The vascular recanalization rate, the total bleeding rate, and the mortality of the two groups were compared. Results The blood vessel recanalization rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The total bleeding rate of the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). The mortality of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). Conclusion Recombinant Human Prourokinase intravenous thrombolysis in the treatment of acute ST-segment elevation myocardial infarction can increase the vascular recanalization rate and reduce the bleeding rate after treatment, the mortality of patients is extremely low.
薛厚君;贺婷. 重组人尿激酶原静脉溶栓治疗急性ST段抬高型心肌梗死的效果观察[J]. 中国当代医药, 2021, 28(19): 86-88转92.
XUE Hou-jun HE Ting. Observation on the effect of intravenous thrombolysis with Recombinant Human Prourokinase in the treatment of acute ST-segment elevation myocardial infarction. 中国当代医药, 2021, 28(19): 86-88转92.